Packages (Simulation)
Reagent Preparation
Image (I)
Image (II)
Certificate
ELISA Kit for Glypican 3 (GPC3)
DGSX; OCI5; SDYS; SGB; SGBS1; MXR7; Glypican Proteoglycan 3; GTR2-2; Intestinal protein OCI-5; Secreted glypican-3
- Product No.SEA971Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample Typeserum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3h
- Detection Range0.156-10ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.062ng/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
- FOB
US$ 398
For more details, please contact local distributors! US$ 568 US$ 2556 US$ 4828 US$ 39760
Specificity
This assay has high sensitivity and excellent specificity for detection of Glypican 3 (GPC3).
No significant cross-reactivity or interference between Glypican 3 (GPC3) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Glypican 3 (GPC3) and the recovery rates were calculated by comparing the measured value to the expected amount of Glypican 3 (GPC3) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 78-99 | 95 |
EDTA plasma(n=5) | 90-104 | 94 |
heparin plasma(n=5) | 98-105 | 101 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Glypican 3 (GPC3) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Glypican 3 (GPC3) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Glypican 3 (GPC3) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 79-101% | 78-94% | 82-89% | 88-98% |
EDTA plasma(n=5) | 88-101% | 78-94% | 94-105% | 78-96% |
heparin plasma(n=5) | 93-101% | 90-104% | 87-94% | 87-97% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
Standard | 2 | Standard Diluent | 1×20mL |
Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
Detection Reagent B | 1×120µL | Assay Diluent B | 1×12mL |
TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.
GIVEAWAYS
INCREMENT SERVICES
- Single-component Reagents of Assay Kit
- Lysis Buffer Specific for ELISA / CLIA
- Quality Control of Kit
- ELISA Kit Customized Service
- Disease Model Customized Service
- Serums Customized Service
- TGFB1 Activation Reagent
- Real Time PCR Experimental Service
- Streptavidin
- Fast blue Protein Stain solution
- Single-component Reagents of FLIA Kit
- Streptavidin-Agarose Beads
Magazine | Citations |
Nature and Science | Diagnostic Role of Serum Glypican-3 as a Tumor Marker for Hepatocellular Carcinoma Sciencepub:10043238 |
Journal of Applied Pharmaceutical Science | Cytotoxic effects of antiglypican-3 against HepG2 cell line Ebscohost: Source |
Asian Pacific Journal of Cancer Prevention | Can Glypican3 be Diagnostic for Early Hepatocellular Carcinoma among Egyptian Patients? Pubmed: 24460300 |
Clin Biochem. | Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: A systematic review and meta-analysis Pubmed: 24362268 |
Science and Nature | Diagnostic Role of Serum Glypican-3 as Hepatocellular Carcinoma Zolcat: Source |
Alexandria Journal of Medicine | Role of serum glypican-3 in the diagnosis and differentiation of small hepatocellular carcinoma from hepatitis-C virus cirrhosis ScienceDirect: S2090506814000062 |
J Egypt Natl Canc Inst. | Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients. Pubmed:24841158 |
European Journal of Pharmacology | Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma Pubmed:25449037 |
Hepatobiliary Pancreat Dis Int | Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern abstract:abstract4525.shtml |
Clinical and Molecular Hepatology | Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis pmc:articles |
Wiley | Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment pubmed:28621802 |
Biomedicine & Pharmacotherapy | Cytotoxic and partial hepatoprotective activity of sodium ascorbate against hepatocellular carcinoma through inhibition of sulfatase-2 and Pubmed:29669302 |
Journal of Cancer and Clinical Oncology | Development and Validation of a Two-Site Immunoradiometric assay for Glypican-3 in plasma: Implication in Diagnosis of Hepatocellular Carcinoma Researchgate:Source |
Turkish journal of oncology | Serum Glypican-3, Vascular Endothelial Growth Factor, and Interleukin-6 Levels in Hepatocellular Carcinoma 10.5505:tjo.2018.1742 |
Intensive Care Medicine Experimental | Elevated plasma glypicans are associated with organ failure in patients with infection Pubmed: 30618011 |
VALUE OF SERUM GLYPICAN 3 AS A PREDICTIVE TOOL FOR EARLY DIAGNOSIS OF HEPATOCELLULAR CARCINOMA (HCC) | |
ADVANCED RESEARCHES | Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C |
Life Sci | Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and … Pubmed:35640776 |
Catalog No. | Related products for research use of Homo sapiens (Human) Organism species | Applications (RESEARCH USE ONLY!) |
RPA971Hu02 | Recombinant Glypican 3 (GPC3) | Positive Control; Immunogen; SDS-PAGE; WB. |
APA971Hu02 | Active Glypican 3 (GPC3) | Cell culture; Activity Assays. |
RPA971Hu01 | Recombinant Glypican 3 (GPC3) | Positive Control; Immunogen; SDS-PAGE; WB. |
APA971Hu01 | Active Glypican 3 (GPC3) | Cell culture; Activity Assays. |
PAA971Hu01 | Polyclonal Antibody to Glypican 3 (GPC3) | WB; IHC; ICC; IP. |
MAA971Hu21 | Monoclonal Antibody to Glypican 3 (GPC3) | WB; IHC; ICC; IP. |
MAA971Hu22 | Monoclonal Antibody to Glypican 3 (GPC3) | WB; IHC; ICC; IP. |
MAA971Hu24 | Monoclonal Antibody to Glypican 3 (GPC3) | WB; IHC; ICC; IP. |
MAA971Hu23 | Monoclonal Antibody to Glypican 3 (GPC3) | WB; IHC; ICC; IP. |
MAA971Hu25 | Monoclonal Antibody to Glypican 3 (GPC3) | WB; IHC; ICC; IP. |
FAA971Hu82 | FITC-Linked Anti-Glypican 3 (GPC3) Monoclonal Antibody | Flow cytometry. |
SEA971Hu | ELISA Kit for Glypican 3 (GPC3) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA971Hu | Multiplex Assay Kit for Glypican 3 (GPC3) ,etc. by FLIA (Flow Luminescence Immunoassay) | FLIA Kit for Antigen Detection. |